Komersova K, Rogerson J W, Conway E L, Lim T C, Brown D J, Krum H, Jackman G P, Murdoch R, Louis W J
Department of Clinical Pharmacology and Therapeutics, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
Br J Clin Pharmacol. 1995 Feb;39(2):207-9. doi: 10.1111/j.1365-2125.1995.tb04435.x.
The effects of the potassium channel opener levcromakalim (BRL 38227) 7.5 micrograms kg-1 were examined on urodynamic variables and blood pressure during inflow and voiding cystometry in six high spinal cord lesion patients. Levcromakalim administration significantly increased the duration of bladder contraction (197 +/- 128 s to 267 +/- 167 s, P < 0.05) and also reduced blood pressure (126 +/- 13/67 +/- 9 mm Hg to 104 +/- 25/52 +/- 12 mm Hg) but was without effect on other urodynamic parameters. Because of concerns about hypotensive responses, further studies involving higher doses of levcromakalim should be considered only if the drug was administered intravesically.
研究了钾通道开放剂左旋克罗卡林（BRL 38227，7.5微克/千克）对6例高位脊髓损伤患者在膀胱充盈和排尿膀胱测压期间尿动力学参数及血压的影响。给予左旋克罗卡林后，膀胱收缩持续时间显著延长（从197±128秒增至267±167秒，P<0.05），血压也降低（从126±13/67±9毫米汞柱降至104±25/52±12毫米汞柱），但对其他尿动力学参数无影响。鉴于对低血压反应的担忧，仅当药物经膀胱内给药时，才应考虑开展涉及更高剂量左旋克罗卡林的进一步研究。
